Stem cell mobilization in multiple myeloma patients: do we need an age-adjusted regimen for the elderly?
The upper age limit for autologous progenitor cell transplantation in multiple myeloma patients is increasing continuously. We examined whether this shift in the age of pretreated myeloma patients requires modification of mobilization regimen. We compared retrospectively 21 consecutive progenitor cell mobilizations in 15 pts < 60 years (median age 56, range 37-59) with 33 consecutive mobilizations in 23 pts > 60 years (median age 65, range 60-73) of age. The number of CD34 positive circulating cells before scheduled leukapheresis was a mean of 67,935 cells/mL (SEM +/- 17,614) in the younger population and a mean of 19,069 (SEM +/- 5,396) for older pts (P = 0.0027). In patients >60 years, 13/33 mobilizations (including 2 patients with 2 failing attempts) were not successful (39%), compared to 6/21 mobilizations (29%, including 1 patient with 3 failing attempts) in the younger population. The increased number of progenitor cells in the grafts of younger patients led to a more rapid regeneration of leukocytes and platelets after stem cell infusion. Our data show that stem cell mobilization in older multiple myeloma patients is inferior compared to a younger patient population. There is a trend towards more leukapheresis until the target stem cell dose has been collected, and the decreased number of progenitor cells in the actual graft delays engraftment of leukocytes and platelets. The overall number of unsuccessful mobilization attempts, however, did not differ significantly between both age groups. A special "age-adjusted" increase in the dose of growth factors seems unjustified. Improvements in timing of leukapheresis, growth factor application, and mobilizing chemotherapy regimen as well as the use of alternative cytokines should be investigated for both age groups.
Fietz
T
T
thomas.fietz@charite.de
Rieger
K
K
Dimeo
F
F
Blau
I W
IW
Thiel
E
E
Knauf
W U
WU
D000328:Adult; D000367:Age Factors; D000368:Aged; D018952:Antigens, CD34 / Q000096:biosynthesis; D001772:Blood Cell Count; D001792:Blood Platelets / Q000166:cytology; D002469:Cell Separation; D016207:Cytokines / Q000378:metabolism; D005434:Flow Cytometry; D016179:Granulocyte Colony-Stimulating Factor / Q000378:metabolism; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods*; D006801:Humans; D007937:Leukapheresis / Q000379:methods*; D007962:Leukocytes / Q000166:cytology; D008875:Middle Aged; D009101:Multiple Myeloma / Q000378:metabolism / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors
D018952:Antigens, CD34; D016207:Cytokines; D016179:Granulocyte Colony-Stimulating Factor